CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 320 enrolled
Drug / intervention
Omega-3 Fatty Acid-Based Parenteral Nutrition +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02321202
NCT02321202Phase 4Completed
CompareCT.gov

Omega-3 Fatty Acid-Based Parenteral Nutrition Improves Postoperative Recovery for Cirrhotic Patients With Liver Cancer

Huazhong University of Science and Technology·interventional·Posted Dec 22, 2014·Updated Aug 22, 2018

In Brief

A Phase 4 clinical trial evaluating Omega-3 Fatty Acid-Based Parenteral Nutrition and Structolipid for Liver Cancer and Cirrhosis. Completed, enrolled 320 participants across 1 site.

Detailed Summary

The safety and efficacy of ω-3 fatty acid in patients with liver cancer followed hepatectomy is not known. This study provided evidences that ω-3 fatty acid-based parenteral nutrition improved postoperative recovery for cirrhotic patients with liver cancer underwent hepatectomy..

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Cancer, Cirrhosis
CountriesChina
Collaborators--

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 22, 2014
Enrollment StartMar 1, 2010
Primary CompletionSep 1, 2013
Study CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 11.5 years ago

Interventions

Omega-3 Fatty Acid-Based Parenteral Nutritiondrug

Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an "All-In-One" manner. 20% Structolipid and 10% Omegaven (ω-3 fatty acid \[FA\] mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively.

Structolipiddrug

Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an "All-In-One" manner. 20% Structolipid and 10% Omegaven (ω-3 FA mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively.